Mechanism of Action
NPFF Receptor System
NPFF signals through two Gi/Go-coupled receptors: NPFF1R (predominantly supraspinal, hypothalamic) and NPFF2R (predominantly spinal, dorsal horn). Both receptors inhibit adenylyl cyclase and modulate calcium and potassium channels in pain-processing neurons. NPFF2R in the dorsal horn is the primary mediator of anti-opioid effects on spinal analgesia.
Anti-Opioid and Tolerance Mechanisms
NPFF acts as a functional opioid antagonist at the spinal and supraspinal level by counterbalancing mu-opioid receptor signaling without directly blocking opioid receptors. Sustained opioid use increases NPFF release, contributing to analgesic tolerance through NPFF2R-mediated desensitization of opioid signaling pathways. NPFF receptor antagonists can restore opioid sensitivity in tolerant animals.
Cardiovascular and Metabolic Actions
NPFF exerts pressor effects through sympathetic activation when administered centrally, increasing blood pressure and heart rate via hypothalamic NPFF1R. Peripheral NPFF receptors on the heart and vasculature mediate opposite (depressor) effects. NPFF also modulates food intake, with central NPFF reducing feeding in satiated but not fasted animals.
Research Summary
Opioid Tolerance and Addiction
AnimalNPFF receptor antagonists (BIBP3226, RF9) prevent or reverse morphine analgesic tolerance in rodent models without affecting baseline pain sensitivity. NPFF systems are activated during opioid withdrawal, and NPFF antagonism reduces withdrawal symptom severity. This positions the NPFF system as a therapeutic target for reducing opioid dependence.
Pain Modulation
AnimalNPFF produces both hyperalgesic and anti-analgesic effects depending on dose and route of administration. Spinal NPFF2R activation reduces opioid analgesia, while some NPFF actions in the brain produce mild analgesia. This biphasic and site-dependent pharmacology reflects the complex integration of NPFF into pain regulatory circuits.
Cardiovascular Regulation
AnimalIntrathecal NPFF produces hypotension through inhibition of sympathetic outflow, while central (ICV) NPFF produces hypertension. These opposing cardiovascular effects highlight the importance of delivery route in NPFF research and suggest potential applications in autonomic blood pressure regulation.
Calculate your Neuropeptide FF dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-opioid research | 0.1-10 nmol | Single or repeated central injection | Intrathecal or ICV (animal) |
| Pain modulation | 1-100 nmol/kg | Single dose | Subcutaneous (animal) |
NPFF research is primarily conducted with central delivery due to poor CNS penetration of peripheral administration. Human applications require development of CNS-penetrant NPFF analogs or antagonists.
Interactions
Safety Profile
NPFF has been studied only in animal models with central delivery methods not applicable to general research or human use. No human safety data exists for exogenous NPFF. The anti-opioid system role suggests NPFF could reduce analgesic efficacy if levels were elevated, representing a pharmacodynamic rather than direct toxicity concern. NPFF receptor antagonists, not agonists, may represent the more therapeutically tractable approach.
References
- [1]Yang HY, et al. FMRF-amide-like immunoreactivity: a new substance in mammalian spinal cord and dorsal root ganglion. Life Sci. 1985.
- [2]Malin DH, et al. Neuropeptide FF (FMRF-NH2-like peptide) produced opioid antagonism in the formalin test in the rat. Peptides. 1990.
- [3]Mouledous L, et al. Neuropeptide FF receptors as novel targets for opioid-modulating drugs. Drug Dev Res. 2010.